Weekender 11/4/16

Welcome to the latest edition of  BioLines Weekender,  featuring the latest news on New Jersey’s innovative biopharma community. Congrats to BioNJ Board Member Anthony Marucci and Celldex Therapeutics on the announcement of the intended acquisition of Kolltan Pharmaceuticals. Anthony and Celldex are 2005 spinouts of the former Medarex which was later acquired by Bristol-Myers Squibb. This week,… Read the full article


Weekender 10/21/16

Welcome to this week’s edition of our newly designed BioLines Weekender,  featuring the latest news on New Jersey’s innovative biopharma community. From Eli Lilly and Company‘s FDA approval of LARTRUVO™ in combination with Doxorubicin for soft tissue sarcoma to the Fast Track designation by the FDA for Chromocell‘s drug candidate (in collaboration with Astellas Pharma) CC8464/ASP1807 for the management of… Read the full article


Weekender 10/7/16

Welcome to the newly designed BioLines Weekender. Our new format allows for easier reading on mobile devices. And, our user-friendly links allow you to easily register for BioNJ events, as well as add them to your Outlook calendar. To access full articles, please click on the article’s title. The Weekender continues to feature the meaningful… Read the full article


Weekender 9/23/16

Welcome to an early edition of BioLines Weekender as this Friday, the BioNJ Team is headed to BioNJ’s CEO Summit at the Bridgewater Marriott. An industry trademark event, the CEO Summit will bring together nearly 300 biotech/pharma C-Suite leaders and their teams, investors, entrepreneurs, academics and other members of the diverse life sciences community to share their knowledge, experiences and views on… Read the full article


Weekender 9/9/16

In tribute to our industry as well as New Jersey, BioNJ and our 4th Annual CEO Summit, BioNJ’s President and CEO, Debbie Hart; Lt. Governor Kim Guadagno; along with Board members and other industry members had the honor yesterday of ringing the opening bell of the NASDAQ. The opening was featured on four national news… Read the full article


Weekender 8/26/16

Many of New Jersey’s innovative biopharma companies advanced recently on their way to new FDA drug approvals, including BioNJ Members Scynexis, Soligenix and Eli Lilly & Co., giving fresh hope to Patients and their families around the world. Because Patients Can’t WaitSM, BioNJ is excited for our fall lineup of events — bringing together the… Read the full article


Weekender 8/12/16

In this week’s edition of the BioLines Weekender we introduce a new section entitled “Economic Developments.” In addition to highlighting the numerous companies moving to the Garden State, we will be spotlighting those expanding their footprint, such as BioNJ Member Allergan. This week, Allergan announced that its new U.S. Administrative Headquarters, expected to be completed… Read the full article


Weekender 7/29/16

Hope for Patients Around the World… New Jersey companies once again are represented at the global forefront of developing important drugs to meet significant unmet medical needs, as recognized in recent announcements from Janssen Therapeutics, Sanofi, Eli Lilly and Company and Eisai. Enjoy this week’s edition of the BioLines Weekender chock full of stories of… Read the full article


Weekender 7/15/16

BREAKING NEWS A big legislative win — G.M.O. Labeling Bill gains House approval. Click here to read the full article. Welcome to this week’s edition of the BioLines Weekender filled with stories of hope for patients around the globe. Delivering life-changing therapies and cures, New Jersey’s medical innovation and drug development and commercialization capabilities are… Read the full article


Weekender 7/1/16

This week’s edition of the BioLines Weekender features lots of advances in the New Jersey ecosystem, including BioNJ Member The Medicines Company’s announcement that its investigational antibiotic, CARBAVANCE® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial in patients with cUTI. Congrats to The Medicines Company Team… Read the full article